(Toronto, ON) January 13, 2017– With lab results being the foundation of more than 70% of all health care decisions, time is always of the essence. As part of LifeLabs' commitment to leading innovation and deliver quality information when patients and their health care providers need it most, we are pleased to announce a new partnership with Seegene Inc. to conduct verification studies of its molecular diagnostic technology.
Testing for ova and parasites in stool samples is a highly manual process and one where the use of technology can improve quality and efficiency. The ability to deliver high quality microbiology results within rapid turnaround times is a critical differentiator in the field of diagnostics. Incorporating the Seegene Allplex panel and technology for parasites will help in the detection of the six most common parasites Giardia lamblia, Entamoeba histolytica, Cryptosporidium spp., Blastocystis hominis, Dientamoeba fragilis and Cyclospora cayetanensis. Achieved through the use of MuDT technology assays (multiplex real time PCR without melting curve analysis) this will provide very high sensitivity and rapid turnaround time to best meet the needs of our clients and health care providers.
The Seegene technology is the latest in a long line of innovations, including the implementation of high volume chemistry lines across the country; the launch of the PULS test; and our continued investments in the areas of genetics and functional medicine, that demonstrate how LifeLabs is consistently pioneering best practices and setting new industry standards to build a healthier Canada.
LifeLabs is a Canadian-owned company with over 50 years of experience providing laboratory testing services to help healthcare providers diagnose, treat, monitor and prevent disease in patients. In communities across British Columbia and Ontario, LifeLabs delivers cost-effective, convenient access to laboratory testing services essential for optimal outcomes in healthcare. LifeLabs employs approximately 5,400 professionally trained staff and delivers over 100 million laboratory tests, supporting over 19 million patient visits annually. In 2013, LifeLabs acquired BC Biomedical in British Columbia and CML HealthCare in Ontario making LifeLabs the largest community laboratory in Canada. LifeLabs is indirectly owned by OMERS Administration Corporation, whose interest is managed by Borealis Infrastructure. In addition to being the first community lab to conduct non-invasive prenatal testing in Canada, LifeLabs is the first lab to provide online appointment booking for patients, non-fasting protocols and secure, on-line access to lab results for patients. For more information about LifeLabs, visit:
Seegene is the world's leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene's core enabling technologies – DPO™, TOCE™, and MuDT™ - are the foundation for M-MoDx tests that can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility. Seegene's products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene's mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies. For more information, please visit
For media inquiries, please contact: